Clinical Trial Update: Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of AI-081, a bispecific antibody targeting PD-1 and VEGF, in advanced solid tumors; the trial is evaluating safety, pharmacokinetics, and prelim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• AI-081

Snippet

Sponsor: OncoC4, Inc. | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING